About xortx therapeutics inc - XRTX
XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.
XRTX At a Glance
XORTX Therapeutics, Inc.
3710-33rd Street NW
Calgary, Alberta T2L 2M1
| Phone | 1-403-455-7717 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -2,656,304.00 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
XRTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.877 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.583 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.02 |
XRTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -885,434.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
XRTX Liquidity
| Current Ratio | 1.615 |
| Quick Ratio | 1.615 |
| Cash Ratio | 1.443 |
XRTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -78.38 |
| Return on Equity | -98.001 |
| Return on Total Capital | -125.194 |
| Return on Invested Capital | -98.001 |
XRTX Capital Structure
| Total Debt to Total Equity | 1.789 |
| Total Debt to Total Capital | 1.757 |
| Total Debt to Total Assets | 1.389 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |